Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Myosin Therapeutics

Request full access

Privately-held biopharmaceutical company developing novel medications targeting cellular motor proteins, specialized molecular machines that convert energy into mechanical work inside cells

Jupiter, United StatesFounded 2020Biotech & Life Sciences

About Myosin Therapeutics

Myosin Therapeutics, a biopharmaceutical company established in 2020, is the result of a collaboration between Dr. Courtney Miller, Dr. Pat Griffin, and Dr. Ted Kamenecka, all of whom have ties to Scripps Research. Dr. Miller, a neuroscientist, made a key discovery that underpins the company's focus: the identification of nonmuscle myosin II as a therapeutic target for conditions like methamphetamine use disorder.

The company is centered on the development of novel medications that target cellular motor proteins, specifically non-muscle myosin II (NMII). This protein is implicated in tumor proliferation and invasion, resistance to therapy, and oxidative stress. Myosin Therapeutics is leveraging this understanding to develop treatments for central nervous system-based disorders, with a particular emphasis on glioblastoma and substance use disorders.

One of the company's lead candidates, MT-125, is a selective inhibitor of NMII. In a significant milestone, Myosin Therapeutics received FDA clearance to initiate a first-in-human trial of MT-125 for the treatment of glioblastoma. The company has secured $3 million in seed funding to advance its research and development efforts.

Source: Dealroom company data

Myosin Therapeutics in the Jupiter ecosystem

Live from Dealroom

The Myosin Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed8 investors entered at this stage

  • Mint12 Pharma
  • Florida Opportunity Fund
  • DeepWork Capital
  • Sontag foundation
  • Mayo Clinic Business Development
  • National Institutes of Health
  • National Cancer Institute (NCI)
  • Florida Department of Health
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Myosin Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Myosin Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.